Literature DB >> 18056890

Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.

Giovanni Musso1, Roberto Gambino, Simona Bo, Barbara Uberti, Giampaolo Biroli, Gianfranco Pagano, Maurizio Cassader.   

Abstract

OBJECTIVE: The ability of the Adult Treatment Panel III (ATP III) criteria of metabolic syndrome to identify insulin-resistant subjects at increased cardiovascular risk is suboptimal, especially in the absence of obesity and diabetes. Nonalcoholic fatty liver disease (NAFLD) is associated with insulin resistance and is emerging as an independent cardiovascular risk factor. We compared the strength of the associations of ATP III criteria and of NAFLD to insulin resistance, oxidative stress, and endothelial dysfunction in nonobese nondiabetic subjects. RESEARCH DESIGN AND METHODS: Homeostasis model assessment of insulin resistance (HOMA-IR) >2, oxidative stress (nitrotyrosine), soluble adhesion molecules (intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin), and circulating adipokines (tumor necrosis factor-alpha, leptin, adiponectin, and resistin) were cross-sectionally correlated to ATP III criteria and to NAFLD in 197 unselected nonobese nondiabetic subjects.
RESULTS: NAFLD more accurately predicted insulin resistance than ATP III criteria: sensitivity 73 vs. 38% (P = 0.0001); positive predictive value: 81 vs. 62% (P = 0.035); negative predictive value 87 vs. 74% (P = 0.012); positive likelihood ratio 4.39 vs. 1.64 (P = 0.0001); and negative likelihood ratio 0.14 vs. 0.35 (P = 0.0001). Adding NAFLD to ATP III criteria significantly improved their diagnostic accuracy for insulin resistance. Furthermore, NAFLD independently predicted HOMA-IR, nitrotyrosine, and soluble adhesion molecules on logistic regression analysis; the presence of NAFLD entailed more severe oxidative stress and endothelial dysfunction, independent of adiposity or any feature of the metabolic syndrome in insulin-resistant subjects.
CONCLUSIONS: NAFLD is more tightly associated with insulin resistance and with markers of oxidative stress and endothelial dysfunction than with ATP III criteria in nonobese nondiabetic subjects and may help identify individuals with increased cardiometabolic risk in this population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056890     DOI: 10.2337/dc07-1526

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  57 in total

1.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

Review 2.  The clinical significance of pancreatic steatosis.

Authors:  Mark M Smits; Erwin J M van Geenen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02-08       Impact factor: 46.802

3.  Coexistence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males.

Authors:  Rui Wang; Qiang Lu; Ji Feng; Fuzai Yin; Chunmei Qin; Bo Liu; Yali Liu; Xiaoli Liu
Journal:  Endocrine       Date:  2011-07-28       Impact factor: 3.633

4.  Vague relationship between alcohol consumption and metabolic syndrome in nonobese people.

Authors:  Kei Nakajima; Masafumi Saito
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

Review 5.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.

Authors:  Jung Sub Lim; Michele Mietus-Snyder; Annie Valente; Jean-Marc Schwarz; Robert H Lustig
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

Review 6.  Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.

Authors:  Alexandra Jichitu; Simona Bungau; Ana Maria Alexandra Stanescu; Cosmin Mihai Vesa; Mirela Marioara Toma; Cristiana Bustea; Stela Iurciuc; Marius Rus; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Diagnostics (Basel)       Date:  2021-04-12

7.  Effect of testosterone administration on liver fat in older men with mobility limitation: results from a randomized controlled trial.

Authors:  Grace Huang; Shalender Bhasin; Elizabeth R Tang; Adam Aakil; Stephan W Anderson; Hernan Jara; Maithili Davda; Thomas G Travison; Shehzad Basaria
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-01-04       Impact factor: 6.053

8.  Usefulness of ultrasonographic estimation of preperitoneal and subcutaneous fat thickness in the diagnosis of nonalcoholic fatty liver disease in diabetic patients.

Authors:  Kazuto Fukuda; Yasushi Seki; Masahiro Ichihi; Takuya Okada; Ayumu Hirata; Sachiyo Kogita; Yoshiyuki Sawai; Takumi Igura; Mamiko Tsugawa; Yasuharu Imai
Journal:  J Med Ultrason (2001)       Date:  2015-02-11       Impact factor: 1.314

Review 9.  Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?

Authors:  Gábor Firneisz
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 10.  Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.

Authors:  Norberto C Chavez-Tapia; Felix I Tellez-Avila; Giorgio Bedogni; Lory S Crocè; Flora Masutti; Claudio Tiribelli
Journal:  BMC Gastroenterol       Date:  2009-10-09       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.